Application of the DAWN clinical imaging mismatch and DEFUSE 3 selection criteria: benefit seems similar but restrictive volume cut-offs might omit potential responders.

C DucrouxN KhouryA LeclerR BlancA ChetritH RedjemG CiccioS SmajdaSimon EscalardJ-P DesillesM MazighiM Ben MaachaM PiotinRobert Fahed

Published in: European journal of neurology (2018)

The results of the DAWN and DEFUSE 3 trials were externally validated in a UOS cohort where the trials' selection criteria identified a similar proportion of responders to thrombectomy.

Keyphrases

high resolution
acute ischemic stroke
risk assessment
human health
photodynamic therapy
fluorescence imaging